Xigris (Eli Lilly & Co)
Xigris (Eli Lilly & Co) - General Information
Human Protein C that has been enzymatically activated by cleavage with thrombin and subsequently purified. Xigris (Eli Lilly & Co) (activated) is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond.
Pharmacology of Xigris (Eli Lilly & Co)
Activated Protein C exerts an antithrombotic effect by inhibiting (cleaving) Factors Va and VIIIa. In vitro data indicate that Activated Protein C has indirect profibrinolytic activity through its ability to inhibit plasminogen activator inhibitor-1 (PAI-1) and limiting generation of activated thrombin-activatable-fibrinolysis-inhibitor. The net effect is the reduction or elimination of blood clots
Xigris (Eli Lilly & Co) for patients
Xigris (Eli Lilly & Co) Interactions
Drug interaction studies with Xigris have not been performed in patients with severe sepsis. However, since there is an increased risk of bleeding with Xigris, caution should be employed when Xigris is used with other drugs that affect hemostasis. Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (unfractionated heparin up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products. Concomitant use of prophylactic low dose heparin did not appear to affect safety, however, its effects on the efficacy of Xigris have not been evaluated in an adequate and well-controlled clinical trial.
Drug/Laboratory Test Interaction
Because Xigris may affect the APTT assay, Xigris present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays). This interference may result in an apparent factor concentration that is lower than the true concentration. Xigris present in plasma samples does not interfere with one-stage factor assays based on the PT (such as factor II, V, VII, and X assays).
Xigris (Eli Lilly & Co) Contraindications
Xigris increases the risk of bleeding. Xigris is contraindicated in patients with the following clinical situations in which bleeding could be associated with a high risk of death or significant morbidity:
Active internal bleeding
Recent (within 3 months) hemorrhagic stroke
Recent (within 2 months) intracranial or intraspinal surgery, or severe head trauma
Trauma with an increased risk of life-threatening bleeding
Presence of an epidural catheter
Intracranial neoplasm or mass lesion or evidence of cerebral herniation
Xigris is contraindicated in patients with known hypersensitivity to drotrecogin alfa (activated) or any component of this product.
Additional information about Xigris (Eli Lilly & Co)
Xigris (Eli Lilly & Co) Indication: For treatment of severe sepsis
Mechanism Of Action: Activated protein C combines with protein S on platelet surfaces and then degrades factor Va and factor VIIIa.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Drotrecogin alfa
Synonyms: Anticoagulant protein C; Autoprothrombin IIA; Blood coagulation factor XIV; Vitamin K-dependent protein C precursor
Drug Category: Antisepsis Agents
Drug Type: Biotech; Approved; Investigational
Other Brand Names containing Drotrecogin alfa: Xigris (Eli Lilly & Co);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: 5.5 hours (mammalian reticulocytes, in vitro).
Dosage Forms of Xigris (Eli Lilly & Co): Powder, for solution Intravenous
Chemical IUPAC Name: Activated human protein C
Chemical Formula: C1786H2779N509O519S29
Drotrecogin alfa on Wikipedia: https://en.wikipedia.org/wiki/Drotrecogin_alfa
Organisms Affected: Humans and other mammals
